王晓刚,陈永康,殷启霖,吴正平
WANG Xiaogang,CHEN Yongkang,YIN Qilin,WU Zhengping

• 1:宜春学院化学与生物工程学院
• 2:南昌大学医学部

摘要(Abstract)：

目的探讨UGT1A1基因多态性对伊立替康化疗患者的安全性及临床药师监护对抗肿瘤药物用药安全性的作用。方法介绍并分析1例UGT1A1基因突变结肠癌患者的诊疗资料。结果拟给予该患者伊立替康320 mg化疗,临床药师根据患者UGT1A1*6纯合突变并结合相关文献报道,推测其发生腹泻或中性粒细胞减少的可能性较高,建议伊立替康减量化疗,于化疗后第13天出现I度骨髓抑制,给予粒细胞集落刺激因子治疗,其后患者血象逐渐恢复,好转出院。结论 UGT1A1基因纯合突变或杂合突变导致UGT1A1对SN-38的代谢能力减弱,导致伊立替康剂量依赖性毒性,临床上UGT1A1基因突变患者,建议伊立替康减量化疗。临床药师应依据药物代谢酶基因多态性基本理论并结合患者实际情况制定个体化、合理化的用药及监护方案,从而确保患者用药安全、有效。
OBJECTIVE To investigate the influence of UGT1 A1 gene polymorphism on the safety of irinotecan chemotherapy,and the role of clinical pharmacists in monitoring the safety of antineoplastic drugs. METHODS One case of colon cancer with UGT1 A1 mutation was introduced and analyzed. RESULTS One colon cancer patient with UGT1 A1 gene mutation intended to use irinotecan 320 mg chemotherapy. Considering the patient UGT1 A1 * 6 homozygous mutation and the relevant literature reported,the clinical pharmacists recommended a low dose of irinotecan for the high risk of diarrhea and neutropenia. In the first 13 days after chemotherapy,low degree of bone marrow suppression was occurred. The blood gradually restored after given granulocyte colony stimulating factor. CONCLUSION Homozygous mutations or heterozygous mutations in the UGT1 A1 gene lead to a decrease in the metabolic capacity of UGT1 A1 to SN-38,resulting in dose dependent toxicity of irinotecan. Reduction dose of irinotecan is recommended for patients with UGT1 A1 mutations in clinical practice. Clinical pharmacists should formulate individualized and rational drug use according to the basic theory of drug metabolizing enzyme gene polymorphism and the actual situation of patients,so as to ensure the safety and effectiveness of medication.

关键词(KeyWords)： 伊立替康;UGT1A1;骨髓抑制;用药监护
irinotecan;UGT1A1;bone marrow suppression;medication monitoring

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王晓刚,陈永康,殷启霖,吴正平
WANG Xiaogang,CHEN Yongkang,YIN Qilin,WU Zhengping

参考文献(References)：

• [1]Levesque E,Belanger A S,Harvey M,et al.Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens[J].J Pharmacol Exp Ther,2013,345(1):95-101.
• [2]Nakamura Y,Soda H,Oka M,et al.Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer:association of UGT1A1*6 and UGT1A1*27 with severe neutropenia[J].J Thorac Oncol,2011,6(1):121-127.
• [3]Hirasawa A,Zama T,Akahane T,et al.Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients[J].J Hum Genet,2013,58(12):794-798.
• [4]Xu C,Tang X,Qu Y,et al.UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer[J].Cancer Chemother Pharmacol,2016,78(1):119-130.
• [5]刘晓玲,杨牡丹,高峻.UDP-葡萄糖醛酸转移酶1A1基因多态性及其与伊立替康化疗不良反应的关系[J].中国药物与临床,2013,13(11):1402-1404.
• [6]Shulman K,Cohen I,Barnett-griness O,et al.Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients[J].Cancer,2011,117(14):3156-3162.
• [7]雷通海,汪洋辉,雷涛,等.国家癌症控制刚要[M].杭州:浙江科学技术出版社,1998:89-91.
• [8]李博,高蕊,李睿,等.药物临床试验不良反应/不良事件关联性判定方法研究探讨[J].中国新药杂志,2014(12):1465-1470.
• [9]O'Dwyer P J,Catalano R B.Uridine diphosphate glucuronosyltransferase(UGT)1A1 and irinotecan:practical pharmacogenomics arrives in cancer therapy[J].J Clin Oncol,2006,24(28):4534-4538.
• [10]段舟萍,彭洪薇,魏筱华,等.UGT1A1*6及*28基因双杂合型患者使用伊立替康联合奈达铂化疗致重度骨髓抑制伴迟发性腹泻1例[J].中国医院药学杂志,2016,36(12):1041-1042.
• [11]Hirose K,Kozu C,Yamashita K,et al.Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene[J].Oncol Lett,2012,3(3):694-698.
• [12]Falvella F S,Cheli S,Martinetti A,et al.DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines,oxaliplatin and irinotecan[J].Br J Clin Pharmacol,2015,80(3):581-588.
• [13]Han F F,Guo G L,Yu D,et al.Associations between UGT1A1*6or UGT1A1*6/*28 polymorphisms and irinotecan induced neutropenia in Asian cancer patients[J].Cancer Chemother Pharmacol,2014,73(4):779-788.
• [14]Yang C,Liu Y,Xi W Q,et al.Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens[J].Drug Des Devel Ther,2015,9:3677-3683.
• [15]Xu C,Tang X,Qu Y,et al.UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer[J].Cancer Chemother Pharmacol,2016,78(1):119-130.
• [16]莫小兰,雷会雯,何艳玲,等.基因多态性影响甲氨蝶呤治疗强直性脊柱炎患者的疗效和毒性[J].今日药学,2017,27(7):483-489.
• [17]Teh L K,hashim H,Zakaria Z A,et al.Polymorphisms of UGT1A1*6,UGT1A1*27&UGT1A1*28 in three major ethnic groups from Malaysia[J].Indian J Med Res,2012,136(2):249-259.
• [18]Tsai S Y,Er T K,Lin C W,et al.Comprehensive analysis of UGT1A1 polymorphisms through high-resolution melting analysis and DNA sequencing[J].Clin Lab,2014,60(6):1015-1026.
• [19]Innocenti F,Schilsky R L,Ramírez J,et al.Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer[J].J Clin Oncol,2014,32(22):2328-2334.
• [20]Xu J M,Wang Y,Ge F J,et al.Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms[J].World J Gastroenterol,2013,19(24):3899-3903.
• [21]张夏兰,王湛,黄立峰,等.依据基因多态性优化伊立替康对结肠癌治疗剂量的药学监护[J].中国临床药理学杂志,2016,32(8):740-741.